Commentary

Podcast

Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO

Author(s):

Brooke McCormick

On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.

On this episode of Managed Care Cast, we're talking with Sreekanth Chaguturu, MD, the chief medical officer of CVS Health.

We discuss the impact of recent pharmaceutical innovations, namely glucagon-like peptide-1 (GLP-1) receptor agonists and biosimilars, on patient health outcomes. Also, we explore the role of trust between patients and providers in adopting new medications, along with initiatives used to reduce drug prices and improve access.

Listen above or on one of these podcast services:

iTunes
TuneIn
Stitcher
Spotify

Related Videos
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
Pierluigi Porcu, MD
Kimberly Westrich, MA, chief strategy officer, NPC
Image credit: Medical technology and futuristic concept. Doctor hologram modern virtual screen interface | SOMKID - stock.adobe.com
Erin Weber, MS
JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)
Marla Black Morgan, MD, Phoebe Neurology Associates
Elizabeth Grush, MBA
Cathy Eng, MD, FACP, FASCO, Vanderbilt-Ingram Cancer Center
Related Content
Image credit: health care costs - Nuttapong punna
April 18th 2025

Cost-Effectiveness Analysis: CKD Screening, SGLT2 Inhibitors Can Reduce Kidney Failure Risk, Racial Disparities

Giuliana Grossi
Initiating chronic kidney disease (CKD) screening at age 55 yielded substantial reductions in kidney failure incidence and improvements in life expectancy across all groups.
Managed Care Cast Thumbnail
April 15th 2025

Personalized Care Key as Tirzepatide Use Expands Rapidly

Maggie L. Shaw John W. Ostrominski, MD
Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
FDA headquarters | Image Credit: Tada Images - stock.adobe.com
April 18th 2025

5 Notable FDA Approvals From March Highlight Advancements Across Therapeutic Areas

Brooke McCormick
From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals last month.
Managed Care Cast Presents: Unlocking the Potential of CGM Technology
April 10th 2025

Managed Care Cast Presents: Unlocking the Potential of CGM Technology

Laura Joszt, MA
A group of experts discusses the use of continuous glucose monitoring (CGM) technology in diabetes and its transformative potential in managing the disease.
Women with HIV | Image credit: LIGHTFIELD STUDIOS - stock.adobe.com
April 16th 2025

Poor Well-Being in HIV Associated With SDOH Adversities

Julia Bonavitacola
Women living with HIV in Canada were found to have worse wellbeing when they had adversities related to social determinants of health (SDOH).
Missy Hopson, PhD
April 16th 2025

Empowering Teams Begins With Human Connection: Missy Hopson, PhD

Kyle Munz Missy Hopson, PhD
Missy Hopson, PhD, Ochsner Health, discussed in detail the challenges of strengthening the patient-centered workforce, the power of community reputation for encouraging health care careers, and the influence of empowered workforces on patient outcomes.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo